VASCULITIS SYNDROMES RAVE about rituximab in ANCA vasculitis?

被引：1
|
作者：
Tarzi, Ruth [1 ]
Pusey, Charles [1 ]
机构：
[1] Hammersmith Hosp, Dept Med, Renal & Vasc Inflammat Sect, London W12 0NN, England
来源：
NATURE REVIEWS NEPHROLOGY | 2013年 / 9卷 / 11期
关键词：
ANTIBODY-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; CYCLOPHOSPHAMIDE; REMISSION; INDUCTION; EFFICACY; THERAPY;
D O I：
10.1038/nrneph.2013.204
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Rituximab is likely to become the standard of care for many patients with ANCA disease. However, an individualized approach is needed to identify those who require more-intense or prolonged therapy.
引用
收藏
页码：628 / 629
页数：2
相关论文
共 50 条
  • [1] Rituximab in ANCA-Associated Vasculitis
    Hassan, Romina I.
    Gaffo, Angelo L.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (02)
  • [2] Rituximab: effective in ANCA-associated vasculitis?
    Schoenermarck, Ulf
    de Groot, Kirsten
    NATURE REVIEWS NEPHROLOGY, 2011, 7 (01) : 6 - 8
  • [3] VASCULITIS SYNDROMES Which maintenance therapy for ANCA vasculitis?
    Nachman, Patrick H.
    NATURE REVIEWS NEPHROLOGY, 2009, 5 (05) : 254 - 256
  • [4] Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
    Turner-Stokes, Tabitha
    Sandhu, Eleanor
    Pepper, Ruth J.
    Stolagiewicz, Natalie E.
    Ashley, Caroline
    Dinneen, Deirdre
    Howie, Alexander J.
    Salama, Alan D.
    Burns, Aine
    Little, Mark A.
    RHEUMATOLOGY, 2014, 53 (08) : 1395 - 1403
  • [5] Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
    Jones, Rachel B.
    Tervaert, Jan Willem Cohen
    Hauser, Thomas
    Luqmani, Raashid
    Morgan, Matthew D.
    Peh, Chen Au
    Savage, Caroline O.
    Segelmark, Marten
    Tesar, Vladimir
    van Paassen, Pieter
    Walsh, Dorothy
    Walsh, Michael
    Westman, Kerstin
    Jayne, David R. W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 211 - 220
  • [6] Rituximab in ANCA-associated vasculitis: a revolution?
    Tervaert, Jan Willem Cohen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (10) : 3077 - 3079
  • [7] Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
    Cortazar, Frank B.
    Muhsin, Saif A.
    Pendergraft, William F., III
    Wallace, Zachary S.
    Dunbar, Colleen
    Laliberte, Karen
    Niles, John L.
    KIDNEY INTERNATIONAL REPORTS, 2018, 3 (02): : 394 - 402
  • [8] Rituximab for ANCA-associated vasculitis: The experience in the United States
    Clain, Jeremy M.
    Specks, Ulrich
    PRESSE MEDICALE, 2013, 42 (04): : 530 - 532
  • [9] Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
    Stone, John H.
    Merkel, Peter A.
    Spiera, Robert
    Seo, Philip
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Clair, E. William St.
    Turkiewicz, Anthony
    Tchao, Nadia K.
    Webber, Lisa
    Ding, Linna
    Sejismundo, Lourdes P.
    Mieras, Kathleen
    Weitzenkamp, David
    Ikle, David
    Seyfert-Margolis, Vicki
    Mueller, Mark
    Brunetta, Paul
    Allen, Nancy B.
    Fervenza, Fernando C.
    Geetha, Duvuru
    Keogh, Karina A.
    Kissin, Eugene Y.
    Monach, Paul A.
    Peikert, Tobias
    Stegeman, Coen
    Ytterberg, Steven R.
    Specks, Ulrich
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 221 - 232
  • [10] Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
    Fenoglio, Roberta
    Roccatello, Dario
    Sciascia, Savino
    KIDNEY & BLOOD PRESSURE RESEARCH, 2020, 45 (06) : 784 - 791
12345